Home › Funds › Regal Partners Ltd › RPRX
Regal Partners Ltd position in RPRX
ROYALTY PHARMA PLC · Health Care
Regal Partners Ltd reported holding 2,447,879 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$137.3M, representing 7.58% of its reported portfolio and ranking #4 among its reported holdings. Regal Partners Ltd has disclosed RPRX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Regal Partners Ltd's RPRX position evolved
Regal Partners Ltd first disclosed a stake in RPRX in Q1 2024 at 959,827 shares (US$29.1M). The position peaked in Q2 2026 at 2,447,879 shares, worth US$137.3M. Across 10 filings, Regal Partners Ltd increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,447,879 shares valued at US$137.3M — a reduction of -176,593 shares quarter over quarter.. Notable position changes include a 84% increase in Q4 2025 (shares rose 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 959.83K | $29.15M | New |
| Q2 2024 | 1.18M | $31.05M | Add |
| Q3 2024 | 1.18M | $33.31M | Hold |
| Q4 2024 | 1.44M | $36.63M | Add |
| Q1 2025 | 1.44M | $44.70M | Hold |
| Q2 2025 | 1.35M | $48.47M | Reduce |
| Q3 2025 | 1.44M | $50.63M | Add |
| Q4 2025 | 2.64M | $102.04M | Add |
| Q1 2026 | 2.62M | $125.90M | Reduce |
| Q2 2026 | 2.45M | $137.25M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 49 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.73M sh · $601.44M · Q2 2026
- Baillie Gifford & Co 10.02M sh · $561.57M · Q2 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 4.32M sh · $242.20M · Q2 2026
- Patient Capital Management, LLC 3.60M sh · $201.79M · Q2 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 2.39M sh · $133.78M · Q2 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $92.92M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $77.67M · Q2 2026
More on Regal Partners Ltd
FAQ
How long has Regal Partners Ltd held RPRX?
Regal Partners Ltd has disclosed RPRX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Regal Partners Ltd's current position in RPRX?
As of Q2 2026, Regal Partners Ltd holds 2.45M shares of RPRX (ROYALTY PHARMA PLC), valued at $137.25M, representing 7.58% of its reported portfolio and ranking #4.
Has Regal Partners Ltd been buying or selling RPRX?
In the latest 13F filing (Q2 2026), Regal Partners Ltd reduced its position in RPRX. The position peaked in Q2 2026 at 2.45M shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.